San Jose State University

SJSU ScholarWorks
Doctoral Projects

Master's Theses and Graduate Research

Spring 4-2017

Developing a Clinical Tool for the Assessment and Diagnosis of
Pediatric Bipolar Disorder
Amanda Jill Horrocks
California State University, Northern California Consortium Doctor of Nursing Practice

Follow this and additional works at: https://scholarworks.sjsu.edu/etd_doctoral
Part of the Psychiatric and Mental Health Nursing Commons

Recommended Citation
Horrocks, Amanda Jill, "Developing a Clinical Tool for the Assessment and Diagnosis of Pediatric Bipolar
Disorder" (2017). Doctoral Projects. 58.
DOI: https://doi.org/10.31979/etd.9ry3-6ynm
https://scholarworks.sjsu.edu/etd_doctoral/58

This Doctoral Project is brought to you for free and open access by the Master's Theses and Graduate Research at
SJSU ScholarWorks. It has been accepted for inclusion in Doctoral Projects by an authorized administrator of SJSU
ScholarWorks. For more information, please contact scholarworks@sjsu.edu.

ABSTRACT
Developing a Clinical Tool for the Assessment and Diagnosis of Pediatric Bipolar
Disorder
Background: Pediatric bipolar disorder is a significant mental illness,
characterized by changes in mood that can be abrupt, unpredictable, and extreme. The
rate of diagnosis of this disorder has been increasing in recent decades. Purpose: A
thorough review of existing literature was completed to inform practice. Additionally, a
survey of clinician assessment practices was completed. Combining the information
learned from the literature review, and the data from the clinician survey, a clinical tool
has been created. This tool provides a thorough, multi-phasic process for the assessment
and diagnosis of pediatric bipolar disorder. Method: Mental health clinicians were
surveyed; respondents were obtained via snowball sampling. Chi square analysis was
completed to determine the relationships between the assessment practices used and the
level of licensure of the clinician, the length of time the clinician had been in practice,
and the age range treated by the clinician. Results: No statistically significant results
were identified from the Chi Square analyses. Inconsistency in the assessment strategies
was noted, however. Implications/Conclusions: Further clinician data should be
obtained due to the small sample size (n=16). The resulting tool has been reviewed by a
subject matter expert and will be validated in practice before diffusion.
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CHAPTER 1: INTRODUCTION
Background
Bipolar disorder (BPD) is a serious mental health condition characterized by
recurrent periods of depression and elevated mood; these mood shifts are accompanied by
cognitive and behavioral symptoms (Anderson, Haddad, & Scott, 2012). Dilsaver (2011)
reported an estimated lifetime incidence of bipolar spectrum disorders is between 4.4%
and 6.4%. Pediatric BPD is becoming more prevalent in the United States (US); in 1996
BPD was the least common diagnosis for children receiving inpatient psychiatric care,
and by 2004 it was the most common (Littrell and Lyons, 2010). Contributing factors to
this rise in diagnosis include an expansion of criteria to include a spectrum of BPD’s, and
a greater understanding of the genetic heritability of the condition (Littrell & Lyons,
2010). The incidence rate of BPD in the pediatric population is approximately 2%
(Youngstrom, Jenkins, Jensen-Doss, & Youngstrom, 2012).
Across the lifespan, the implications of BPD are more significant than the other
disorders that have similar clinical presentations, like attention deficit hyperactivity
disorder (ADHD) or oppositional defiant disorder (ODD). Goldstein (2009) reported a
lifetime rate of suicidal ideation of up to 75%, a 44% suicide attempt rate, and a
completed suicide rate of 25% for those with BPD. BPD is also known to be a kindling
illness, making an accurate diagnosis and early treatment important (Weiss et al., 2015).
Kindling refers to the phenomenon whereby the experience of life stress causes mood
cycles to exacerbate in individuals suffering from conditions like BPD (Weiss, et al.,
2015).

2
Purpose
The purpose of this project was to complete a thorough review of existing
literature about pediatric BPD, to conduct a survey amongst mental health clinicians, and
use the information and data obtained from these processes, to create a clinical tool for
the assessment and diagnosis of pediatric BPD. Literature has been reviewed to provide
an evidence-based foundation for the development of the tool. Clinicians were queried
and their responses analyzed to determine the level of licensure, the length of time in
practice, age ranges treated, and assessment strategies employed. Research questions
analyzed were:
1) Is there a significant difference between the type of licensure that a clinician holds
and the assessment strategies used in clinical practice?
2) Is there a significant difference between the length of time a clinician has been in
practice and the assessment strategies used in clinical practice?
3) Is there a difference between the age ranges that clinicians treat and the
assessment strategies used in clinical practice?
Youngstrom, Jenkins, Jensen-Doss, and Youngstrom (2012) proposed several
evidence-based steps that could be followed to assess pediatric BPD, but failed to
incorporate a tool that could be used or medical screening elements. This project created
a process that will incorporate clinical interviewing, obtaining collateral data, completing
valid and reliable screening tools, and obtaining diagnostic studies before assigning this
diagnosis. It is expected that the robust nature of the screening tool will allow for rapid
adoption of the process by clinicians (Dearing, 2009).
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Current assessment practices to diagnose pediatric BPD are often subjective,
inconsistent, and do not follow a cohesive, researched process (Jenkins, Youngstrom,
Youngstrom, Feeny, & Findling, 2011). Additionally, these authors noted that BPD,
compared to other conditions, is more challenging to accurately diagnose due to the
varying mood states in which a patient may present (Jenkins et al., 2011). A patient with
Bipolar I disorder, for example, may present for treatment in full mania, hypomania,
euthymia, dysthymia, severe depression, or a mixed state. Clinicians should conduct
thorough interviews, and incorporate valid screening tools to assist in making a BPD
diagnosis. It is also important to incorporate evidence-based, objective methods of
assessment to reduce diagnostic ambiguity. Accurate, early identification and treatment
will yield more positive patient outcomes due to the initiation of earlier treatment
(Maniscalco & Hamrin, 2008).
It is thought that in some situations pediatric BPD is over diagnosed, and in other
scenarios, it is misdiagnosed as another condition (Danner et al., 2009). Several pediatric
mental health conditions have overlapping symptoms (Youngstrom, Birmaher, &
Findling, 2008), and consequently, this makes accurate diagnosis challenging.
Youngstrom et al. noted that irritable mood, distractibility, and pressured speech are
common in pediatric BPD, but that these symptoms are not sensitive to the condition.
Conduct disorder (CD), ODD, and ADHD all share symptoms in common with pediatric
BPD, and they can be mistaken for each other clinically (Danner, et al., 2009).
Post et al., (2015) noted that there is a life expectancy loss of 13-30 years in
individuals who have a serious mental illness. BPD is considered serious mental illness,
according to DeHert et al., (2011). BPD is a costly public health issue, Dilsaver (2011)
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noted that the economic burden of bipolar I and bipolar II disorders is 151 billion dollars
in the US annually. The significance of these statistics provides support for the diffusion
of the clinical tool as an innovative clinical process. The degree to which the tool can
help to change these statistics should be highlighted to increase the likelihood of adoption
by clinicians. The tool represents an innovation to enhance current assessment strategies,
and the diffusion of the attributes of the tool will aid clinicians in adopting the new
process (Dearing, 2009).
Theoretical Framework
Diffusion of innovation theory provides a foundation and guide for the execution
of this project. This theory involves taking the innovative idea of the clinical tool, and
diffusing its content and use to clinicians, the clinicians choosing to accept the innovative
process, and clinicians adopting the innovation into practice (Dearing, 2009). The
beneficial attributes of the process must be readily identified by clinicians to aid in their
ease of adoption. Information regarding the evidence-based assessment strategies
incorporated, and rationale behind the recommendations for the innovative aspects of the
tool will have to be diffused to clinicians to aid in their adoption process (Dearing, 2009).
The theory suggests that accelerated diffusion of concepts, and thus accelerated adoption
of the innovation can be achieved by incorporating validated concepts (Dearing, 2009).
The clinical tool has achieved this by clustering together several evidence-based
assessment strategies for the first several phases of assessment.
Murray (2009) discussed the application of the diffusion of innovation theory to
psychotherapy practice. Murray reviewed the major tenets of the theory, and ultimately
discussed that clinicians will more readily adopt the innovation into practice if they find
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the research meaningful to their clinical work (Murray, 2009). The clinical tool was
developed with this in mind. Training and dissemination efforts will need to focus on
ensuring clinicians can recognize the value of the new process, as well as its ease of use
and adoption clinically.

CHAPTER 2: LITERATURE REVIEW
Assessment and Diagnosis
Youngstrom, Jenkins, Jensen-Doss, and Youngstrom (2012) reviewed evidencebased assessment strategies used to diagnose pediatric BPD. The authors provided an
algorithm of steps that could be used to assess for this condition, as well as a figure
diagramming the use of these steps. There was no tool or manner in which the presented
process should be applied in the clinical setting. Some similarities include the inclusion
of several commonly utilized evidence-based assessment strategies. Some of the
differences include that the authors of the article provided some steps in their process to
use after a diagnosis of BPD had been assigned; the tool focuses on ruling in or ruling out
the diagnosis. Another difference is that the created clinical tool includes
recommendations for laboratory and imaging studies.
Algorta et al. (2013) completed a non-experimental, correlational study with a
brief screening tool, the Family Index of Risk for Mood Issues (FIRM), to enhance the
accuracy of pediatric BPD diagnoses. This study and resulting tool is aligned with one of
the steps that is proposed by Youngstrom, Jenkins, Jensen-Doss, and Youngstrom (2012).
It does not, however, give a comprehensive process for assessment, but provides a helpful
tool for the clinician to use as a part of the process. The sample included pediatric
subjects aged 5-18 years (average 10.3 years), and their caregivers. All subjects were
seeking an outpatient psychiatric evaluation. Subjects came from 273 families, from
these families, 43 youth were found to be on the bipolar spectrum. Caregivers completed
the Mood Disorder Questionnaire – Parent (PMD-Q), and the FIRM appeared at the end
of the PMD-Q. Caregivers also completed a Child Behavior Checklist (CBCL) about the
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youth subject. Youth subjects were assessed with the Kiddie Schedule for Affective
Disorders and Schizophrenia – present and lifetime (K-SADS-PL), supplemented with
other interview questions. Guardians were assessed for mental health history and were
administered a Mini International Neuropsychiatric Interview (MINI). Logistic
regression was completed to determine if FIRM provided a significant improvement in
the identification of BPD. A t-test was also completed to establish if any test performed
significantly better than another. The FIRM was more sensitive to BPD than other tools
and did not correlate to ADHD. The logistic regression showed that FIRM provided a
significant improvement in detecting BPD. An identified strength of this study was that
the subjects were all assessed in a thorough manner by highly trained research assistants.
An identified limitation of the study was that the demographic characteristics of the
study, with 90% of subjects being from low-income families, likely reduced the
effectiveness of the FIRM. This study is important to this project as it discussed the
FIRM, which is an effective yet easily administered screening tool for the presence of
BPD. The FIRM is included in the resulting tool of this clinical project for its ease of use
and effectiveness.
Providing additional support to the previous two articles, Martelon, Wilens,
Anderson, Morrison, and Wozniak (2012) completed a case-control family study to
explore the link between challenges in the gestational and neonatal periods with the
development of pediatric BPD. Subjects were obtained from two other ongoing similarly
designed studies. There were 98 healthy controls, 120 bipolar patients, and 120 nonaffected siblings included. Subjects under the age of 18 were assessed using the K-SADS
– epidemiologic version (K-SADS-E), and those 18 and older were assessed with the
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Structured Clinical Interview for DSM-IV (SCID). Mothers of all subjects completed a
module of the Diagnostic Interview for Children and Adolescents – Parent Version
(DICA-P). Statistical analyses included Chi square and t tests. A significant relationship
was found between BPD and neonatal challenges. No significant relationship was found
between gestational challenges and the development of BPD. One limitation of this study
is the fact that the DICA-P was completed retrospectively, and there is a chance that
mothers may not accurately remember the significance of any challenges with their
pregnancy or the neonatal period. This study is important to this project as it re-enforces
the need to have a thorough gestational, neonatal, and pediatric history obtained during
the clinical interview. Both Algorta et al. (2013) and Youngstrom, Jenkins, Jensen-Doss,
and Youngstrom (2012) discussed the importance of understanding family history as a
part of the assessment process.
Moving away from the process of assessment into the diagnosis itself, Hafeman et
al. (2013) conducted a non-experimental, case-control study to determine if youth
diagnosed with BPD, not otherwise specified (NOS) were similar to those with BPD I or
BPD II. The sample included 707 children with a mean age of 9.4 years, presenting for
treatment at an identified outpatient clinic. The subjects were evaluated and diagnosed
with BPD I (n=71), BPD II (n=3), BPD NOS (n=88), or no BPD (n=545). Subjects were
assessed using the K-SADS-PL, young mania rating scale (YMRS), K-SADS Depression
Rating Scale, K-SADS Mania Rating Scale (KMRS), and the Children's Global
Assessment Scale (CGAS). BPD II was eliminated from the analysis due to the low
number of subjects with that diagnosis. Analysis of variance (ANOVA) testing was
completed for continuous variables, and Chi square testing for the categorical variables,
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to determine differences between the three remaining groups. BPD NOS showed no
significant difference from BPD I in mood symptoms at baseline. BPD NOS had lower
KMRS than BPD I, but both had significantly elevated scores when compared to no BPD.
CGAS also showed significant impairment in BPD NOS and BPD I compared to no
BPD. An identified strength of this study was the thorough diagnostic assessment given
to the subjects, including a myriad of validated assessment tools. This study is important
to this project as it discussed the similarity in the clinical presentation for different
diagnoses across the BPD spectrum.
Providing a different perspective, Benti, Manicavasagar, Proudfoot, and Parker
(2014) conducted a qualitative study with a phenomenological approach to understand
the early experiences of patients with BPD, and how they differed from those diagnosed
with unipolar depression (UD). Some controversy still exists about diagnosing BPD in
the pediatric population, and this study provided some information about individuals
living with BPD. There were 39 participants aged 18-35 years old; all were diagnosed
before age 24. Twenty participants had UD and 19 had BPD. All participants were given
the MINI, YMRS, and the Hamilton Rating Sale for Depression (HAM-D) by the same
clinician to determine that they were in a state of euthymia at the time of the study. After
determining that they were eligible to participate based on diagnosis, age, and mood state,
the participants completed a semi-structured interview. Descriptive statistics were
obtained for the demographic data of participants. There was a trend noted for a younger
age of onset in BPD than in UD. Indicators for BPD that were revealed included: adverse
home environments, more assertive and disinhibited personalities, and mood swings at a
young age. This study is important to the project as it gives insight to the age and nature
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of the onset of symptoms. This article provides support for the diagnosis and early
treatment of BPD, based on the experiences of the subjects.
Similar to Benti, Manicavasagar, Proudfoot, and Parker (2014), Carpenter-Song
(2009) completed a qualitative study with an ethnographic focus, to learn about the lived
experience of patients and families dealing with mental health issues. One primary
difference from the preceding article is that the previous study involved the patients
recounting their earlier experiences, whereas Carpenter-Song studied pediatric patients
and their families while they were still children. There were 20 families in the study: nine
African American, ten Euro-American, and one Latino. The socioeconomic statuses of
the families ranged from upper middle class to low income. Nineteen children in the
study met criteria for BPD spectrum or ADHD. Youth were evaluated using the KSADS-PL to determine their diagnosis for the study. A semi-structured interview, the
Subjective Experience of Illness and Medications in Youth was used to evaluate
participants. Interviews were conducted in participant homes over multiple sessions.
The study included detailed descriptions of three families and provided some of their
responses to questions about their lived experience. The medicalization of these
conditions was discussed, along with the participant's experiences with providers. An
identified strength of this study is the ethnographic approach that is not taken into
account in many quantitative studies. It is possible that families, like the described
African American families in this study, would not participate in some other quantitative
research because they do not attribute these mental health concerns to individual
pathology. Having all perspectives considered and reported gives strength to this data
and the study. This study is useful for this project as it discussed the lived experience of
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patients and families involved in the mental health system. Additionally, it discussed
important cultural considerations regarding attitudes about mental illness that are
important to consider. Families who do not believe in mental illness or sense stigma
about seeking care might be less likely to seek help or discuss troubling symptoms.
Neurobiological Changes
Chang et al. (2005) conducted a case-control study to examine structures of the
limbic system in patients with BPD and healthy controls. Twenty children and
adolescents with BPD were recruited from an ongoing study. Each of the subjects had a
gender, age, and IQ-matched control recruited from the community. SCID, K-SADS,
and K-SADS-PL were used to evaluate subjects. Bipolar patients were additionally
evaluated with the YMRS. T-tests were used to analyze the data obtained from magnetic
resonance imaging (MRI) studies. No statistical significance was seen between BPD
subjects and controls for total brain volume, thalamus, caudate, and hippocampus. Total
amygdalar volume, as well as right and left amygdalar volume was significantly
decreased in the BPD subjects. Further study showed this reduction to be related to
depletion of gray matter volume (GMV) in the right amygdala. Treatment with lithium
or valproic acid was shown to be somewhat protective of this change. This study
provides support for this project in that it demonstrates underlying neurobiological
processes that appear to be a part of the BPD presentation. It also supports that treatment
of BPD can be protective against this neurobiological change; an important consideration
when considering diagnosing BPD in the pediatric population.
Similar to Chang et al. (2005), Lisy et al. (2011) conducted a study that found
changes in GMV in MRI scans of patients with BPD. Additionally, both studies had
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findings showing that treatment with certain medications for BPD is brain protective.
Lisy et al. completed a longitudinal case-control study to assess changes in GMV in
subjects with BPD and healthy controls. Fifty-eight subjects with BPD and 48 healthy
controls underwent a baseline MRI scan, and then a follow-up scan some months later
(mean of 11months). Assessments were completed using the K-SADS and the SCID
based on the age of the subject. BPD patients were in a variety of mood states at the time
of their baseline MRI. Healthy controls were found to have greater gray matter volume
compared to BPD patients overall. BPD patients, however, had increased gray matter
volume over time. There was a positive correlation in the bipolar group between the
length of time between scans and the change in gray matter volume. BPD patients
receiving antipsychotics or anticonvulsants showed increases in the left frontal gyrus and
the left medial gyrus, respectively. This study did not note a change in GMV between
scans in patients receiving lithium. The longitudinal nature of this study is a strength.
One limitation of this study is that subjects with nicotine dependence were not excluded
from participation, and this has been linked to GMV changes in the past. This study is
important to the project as it demonstrated neurostructural changes related to BPD.
Different from the preceding two studies, Xiao et al. (2013) conducted a casecontrol study to determine neurologic changes of manic pediatric BPD patients. Lisy et
al. (2011) included patients in a variety of mood states, whereas Xiao et al. included only
manic patients. The study by Xiao et al. included 15 patients aged 12 to 17 years old
from outpatient psychiatric clinics in China, and they were age and sex matched with
healthy controls. Subjects met criteria for BPD, had to have one previous manic or
hypomanic episode, and were manic at the time of completing the study. Participants
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were evaluated using the K-SADS-PL, and the Wechsler Abbreviated Scale for
intelligence. BPD patients additionally completed the YMRS. Statistical analysis was
completed using Chi square tests and t tests. MRI scans were completed, and changes
were found in the bilateral hippocampus, right anterior cingulate cortex, right
parahippocampal gyrus, and left caudate. Chang et al. (2005) did not find changes in the
caudate or hippocampal structures like this study did. Some of this could be related to
differences in study design. This study demonstrated neurobiological changes that can be
observed during the resting state, and during task completion in BPD. This study is
important to the project as it outlines some of the neurobiological changes that can be
appreciated in the brain of the bipolar patient compared to a healthy control when there
was no task being completed. This information suggests that objective findings might be
possible when diagnosing pediatric BPD.
Exploring a different aspect of neurobiological function in BPD, Quiroz, Gray,
Kato, and Manji (2008) completed a retrospective review to examine the role of
mitochondrial function in BPD. The authors noted evidence is emerging that
mitochondria play a role in the ability for neurotransmitters to freely move between
neurons. Dysfunction in calcium transportation and utilization is another anomaly that
has been documented in BPD; this could also be linked to mitochondrial function. Over
12,000 hippocampal genes from autopsied brains of patients with BPD, schizophrenia,
and healthy controls were analyzed. Forty-three genes were expressed in a diminished
manner for BPD as opposed to schizophrenia. Forty two percent of these changes were
related to mitochondrial function. It was noted that treatment with lithium and valproic
acid were protective to brain function, similar to the other studies discussed that
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completed MRI scans. This article is important to the project as it explored the biologic
basis for BPD.
Susceptibility Genes and Genetic Linkage
Lichtenstein et al. (2009) conducted a population-based retrospective study to
assess heritability and environmental factors that contribute to susceptibility for
schizophrenia, BPD, or a comorbidity of both conditions. The sample was obtained by
linking national registries. Over nine million potential participants were identified, and
the article stated that over 2 million families were analyzed. Rates of disease in family
members was compared to those with hospitalizations who were the same age and
gender. Different family types were analyzed in an attempt to separate genetic from
environmental factors for susceptibility. A generalized multivariate mixed linear model
was used. Heritability of schizophrenia was estimated to be 64%, and BPD was
estimated to be 59%. An identified limitation was that the data used to determine the
sample was the lack of information about the diagnostic practices of the treating
clinicians. Additionally, they may not utilize a standardized approach to the assessment
of BPD and did not know that their assigned diagnoses would be used for the purpose of
this study. This study supports this project as it demonstrated the high rate of heritability
of BPD, warranting consideration of the genetic factors during the assessment of
potential BPD cases.
Different from Lichtenstein et al. (2009), Barden et al. (2006) completed a casecontrol study to examine three different specific genes as potential factors leaving one
susceptible to developing BPD. The genes studied were: purinergic receptor P2X 7
(P2RX7), purinergic receptor P2X 4 (P2RX4), and calcium/calmodulin dependent protein
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kinase kinase 2 (CAMKK2). Two hundred thirteen individuals from Quebec were
identified using the French version of SCID. There were 214 control subjects. Blood
samples were obtained from all subjects. Fisher’s exact tests were used to analyze data.
Single nucleotide polymorphism’s (SNP) associated with P2RX7 accounted for 56% of
all SNP’s in this genetic area. All three genes studied are implicated in the synaptic use
of calcium and subsequent modulation of neurotransmitters. The data obtained from this
study suggest susceptibility to BPD may exist through P2RX7 and CAMKK2, though
stronger in the former. There was a significant association between 2 markers of P2RX7
in BPD as compared to control subjects. The authors also suggested that due to the space
between implicated susceptibility genes, there may be a gene cluster associated with
BPD. This study is important to this project as it gives discussion to the biological basis
of BPD, and offers some genetic markers that may be implicated in the development of
BPD.
Doyle et al. (2010), explored genetic susceptibility to BPD, and like Barden et al.
(2006), found some genes suggestive of playing a role in the development of the disorder.
Doyle et al. additionally explored the heritability of BPD. The authors completed a nonexperimental, correlational descriptive study to expand on previous research regarding
the diagnosis and genetic basis of pediatric BPD. Subjects were obtained from a group
previously studied in a sibling-pair linkage ADHD project. Subjects aged 6-17 years old
were assessed using the K-SADS-E, and subjects 18 years old and older were assessed
with the SCID. Weschler Intelligence Scales (IQ) were completed for all subjects as
well. A CBCL was completed by guardians of subjects aged 6 to 18 years. Genotyping
was then completed on the subjects. Youth with CBCL data were the focus on of the
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main analysis. The independent variable was the youth with the juvenile BPD phenotype
based on the CBCL scores (CBCL-JBD). Heritability for CBCL-JBD was found. The
genomic scans revealed suggestive linkage for youth with CBCL-JBD at 1p21.1 (changes
with chromosome 1), 6p21.3 (changes with chromosome 6), and 8q21.13 (changes with
chromosome 8), though no genetic markers had a statistically significant correlation to
the phenotype. An identified limitation of this study was that only 54% of CBCL were
returned. This study is important to the project because it discussed the heritability of
BPD, and found some suggestive susceptibility genes, though statistical significance was
not found.
Another exploration of genetic susceptibility for BPD was completed by Jang et
al. (2015), who completed an animal study on transient receptor potential cation channel
subfamily M member 2 (TRPM2) deficient mice, to explore the biologic basis of BPD in
humans. Many behavioral tasks were completed and video recorded. Mice also
underwent electroencephalogram studies and blood tests. Animal handling protocols
were followed, and this study was completed in Korea. One way ANOVA tests were used
to analyze data obtained. This study examined the changes associated with three
mutations of TRPM2. One particular mutation, D543E demonstrated significant changes
in behavior and function. Having these mutations leads to an inappropriate production of
other proteins naturally occurring in the brain. One of these, GSK-3, is known to be
directly related to mood regulation. The nature of this study being an animal study with
interwoven knowledge of human BPD is both a strength and weakness. The strength lies
in the intricate and robust study that was completed, but the weakness is that this has not
been replicated fully in the human population. This study is important to this project by
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providing information that could be directly related to the development of BPD in
humans.
Olivera et al. (2014) explored the genetic factors related to BPD development
from a different perspective. The authors conducted a non-experimental, case-control
study to determine if there was a genetic response to infection or inflammation that leaves
one susceptible to the development of BPD. DNA from 571 French patients with BPD
(229 early onset before age 22, and 342 late onset), and 199 healthy controls were
analyzed for toll-like receptor 2 (TLR2) polymorphisms. All subjects were euthymic at
the time of inclusion, as evidenced by completion of a Montgomery-Asberg Depression
Rating Scale and a Mania Rating Scale. The independent variable was the presence of
BPD, and the dependent variables were the presence or absence of TLR2 polymorphisms.
Genotype frequencies between the early onset, late onset, and healthy controls were
performed using Chi square tests. The TLR2 rs380499 TT and TLR2 rs4696480 TT
genotypes were found to be significantly more present in early onset BPD patients than
late onset. No statistically significant difference was found between the late onset group
and the healthy controls. An identified strength of this study was the homogenous
sample and a large number of sample subjects. This study is relevant to the project as it
provides information regarding background questions that should be asked during the
clinical interview, and identified statistically significant susceptibility genes for pediatric
BPD.
Deepening the body of evidence for genetic linkage, Shifman et al. (2004)
conducted a case-control study to explore the association between catechol-Omethyltransferase (COMT) and BPD. This study was completed in Jerusalem, Israel.
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There were 217 unrelated case subjects; diagnosis was confirmed with the SCID. All
subjects were of Ashkenazi Jewish descent. Control samples were obtained from around
1,050 healthy Ashkenazi individuals. Chi square tests were completed to analyze data
received. Gender specific samples were run, as a gender effect had previously been
identified with COMT. A significant association was found between SNP’s of COMT
and BPD. Based on previous research, the data of this study also demonstrated a
relationship between schizophrenia and BPD. The size of the control group is a strength
of this study. However, the study does not indicate if these controls were screened. Some
controls may have had BPD and did not know it. Though the strength of the correlation
between COMT and BPD has been found to be more modest in the decade since this
research was completed, this article provides support for the completion of this project
due to the relationship found with both BPD and schizophrenia.
Like other studies in this section, Zhou et al. (2009) completed a study to explore
another potential gene leaving individuals susceptible to developing BPD. Zhou et al.
conducted a study that had a correlational component for European Caucasian families,
and a case-control component for Chinese subjects. The study was conducted to
determine if there was a link between Sp4 transcription factor (Sp4) and BPD, as Sp4 is
known to play a role in hippocampal development in animal studies. Ten SNP’s located
across Sp4 were evaluated. RMANOVA tests were used to analyze the data obtained. 4
SNP's were found to be statistically significant and associated with BPD. The number of
subjects and the fact that results were replicated in two different ethnic groups are
strengths of this study. The article is important for the project because it identifies a
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susceptibility gene that was found to be statistically significant in a large sample across
ethnic groups.
Gaps in Research
Literature searches were completed in the CINAHL and PsycINFO databases
using the search terms “assessment diagnosis pediatric bipolar disorder,” “assessment
pediatric bipolar disorder,” and “pediatric bipolar disorder.” Additionally, a search was
completed in both CINAHL and PsycINFO for “susceptibility genes bipolar disorder,” as
there is interest in incorporating emerging information regarding genetic polymorphisms
that are related to BPD into this project. Youngstrom, Birmaher, and Findling (2008)
reviewed the sensitivity and specificity of symptoms to BPD and other conditions.
Studies referenced in the literature review often utilized validated rating scales as a part
of the assessment strategy. This is helpful but does not seem substantial enough, as
diagnostic challenges still exist. Rucklidge (2008) found that retrospective completion of
rating scale tools did not reveal prodromal periods for those patients who were diagnosed
after puberty. They did demonstrate symptoms that were indicative of psychopathology,
however. This re-enforces the need for thorough assessment during the childhood and
adolescent years so that treatment onset is not delayed. Kessing, Vradi, and Andersen
(2015) noted that of those diagnosed with pediatric BPD, 40.7% of patients received the
diagnosis at their first point of contact, but 24% of these patients eventually were given a
different diagnosis after follow up.
Faraone, Glatt, and Tsuang (2003) noted that pediatric BPD is often more severe,
and may be under stronger genetic influence than adult onset BPD. Several genes have
been identified as leaving one susceptible to developing pediatric BPD. One of these
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genes was discussed in the article by Olivera et al. (2014) in the literature review above.
Some of the others include specific polymorphisms of COMT, brain-derived
neurotrophic factor (BDNF), and the dopamine transporter (DAT) (Mick et al., 2008).
Many of these genetic pathways show susceptibility, but none of them provide a direct
pathway to diagnosis based on the current information available. Given the information
available, and considering that no one tool provides a completely reliable pathway to
diagnosis, this project is needed to provide as consistent and clear a path as possible to
diagnosis.

CHAPTER 3: METHODOLOGY
Study Design and Research Questions
The project had several elements: a systematic review of the literature to inform
practice, a survey of clinicians, and the development of a clinical tool that could be
implemented to more thoroughly and consistently assess for pediatric BPD. Research
questions analyzed were:
1) Is there a significant difference between the type of licensure that a clinician holds
and the assessment strategies used in clinical practice?
2) Is there a significant difference between the length of time a clinician has been in
practice and the assessment strategies used in clinical practice?
3) Is there a difference between the age ranges that clinicians treat and the
assessment strategies used in clinical practice?
Sampling and Method
Survey respondents were recruited via snowball sampling; approximately 50-100
respondents were desired to minimize distribution errors in responses (Field, 2013).
Criteria for inclusion required that the respondent be a medical doctor, physician’s
assistant, nurse practitioner, or clinical nurse specialist working in the field of mental
health. Clinicians additionally needed to treat some children or adolescents in their
practice to be included in the survey. Children and adolescents, for this project, were
defined as people aged 3 to 17 years. Clinicians did not have to exclusively treat this age
group and did not need to have any specific portion of their practice be dedicated to the
child and adolescent population. Exclusion criteria are any individuals who did not meet
the aforementioned practice criteria. All subjects were able to provide their informed
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consent to participate in the survey, and none belonged to a protected category of
subjects. Several published studies explore aspects of the existence, assessment, and
diagnosis of pediatric BPD, but there does not appear to be any published English
literature other than Youngstrom, Jenkins, Jensen-Doss, and Youngstrom (2012) that
address a process for assessment. The similarities and differences between their article
and this work were previously explored in this paper.
Respondent participation was voluntary. The respondents received the link for
the survey from people that they know, due to the snowball sampling methodology. The
potential respondent had the sole ability to click the link and begin the survey process.
No investigational, experimental, or special procedures were used in the completion of
the project. Each respondent should have only completed the survey once, as addressed
in the informed consent, and the location of completion was up to the respondent. The
survey could have been completed on any computer or mobile device that could access
the survey website.
Data Collection
The survey (Appendix B) was created via the Survey Monkey platform, and covered six
areas: informed consent to participate, the age range treated by the clinician, the type of
licensure of the clinician, the length of time the clinician had been in practice, what
strategies they used to assess for pediatric BPD, and whether they felt a standardized
assessment process would assist them in the assessment and diagnosis of pediatric BPD.
Survey items contained primarily check box answers, and it was estimated that unless a
clinician chose to write in free text, survey completion took about five to ten minutes.
Institutional Review Board approval from California State University, Fresno was
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obtained. Data was collected from September 13, 2016, through October 12, 2016. No
standardized instruments were used for data collection in this project.
Data Analysis
Emphasis was placed on the descriptive statistics generated from the data
received. This provided information about current practice strategies employed by
clinicians, which substantiated the need for the development of the clinical tool. Three
groupings of variables were subject to statistical analysis. Chi square analysis was
performed on: the age range treated by the clinician and what assessment strategies
employed in practice, length of time in practice and assessment strategies employed in
practice, and level of licensure and assessment strategies employed in practice (Field,
2013a). None of the Chi square analyses resulted in significant findings. However, the
survey data yielded varied assessment and interview strategies (Appendix C).
Potential Benefits
There were no immediate or direct benefits to any respondent who completed the
survey. Any respondent who wishes to receive results of the survey data was provided
information to request this as a part of the informed consent. It was anticipated that
clinicians were likely to see more benefit from the resulting tool that was created, than
from participation in the survey. This tool will guide clinicians through a robust
assessment of possible pediatric BPD, and aid them in more accurately diagnosing this
condition.
Potential Risks
Risks to respondents were minimal for this study. Risks involved the time needed
to complete the survey and any distress that occurred from examining their assessment
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strategies. There were no social, physical, economic, or legal risks anticipated for any
survey respondent. The clinical tool will be validated as a separate endeavor after
completion of this project and academic program, so there was no risk at this time to any
patient. There were no violations of normal expectations.
Precautions to Minimize Risk
Completion of the survey was voluntary and anonymous. At no point during the
survey was any personally identifying information gathered. The respondents completed
the survey in an electronic format. There were no individual survey tools collected by
any other means, and therefore no physical storage or destruction was necessary. Survey
data is accessed by the investigator on the survey website. This website is username and
password protected, preventing any unauthorized access to survey data. Any physical
data that is printed, and not maintained in an electronic form on the secured website, will
be secured in a locked filing cabinet. Data analysis reports from statistical software are
being stored in a biometrically locked laptop computer.

CHAPTER 4: RESULTS
Data from the clinician survey was analyzed using IBM SPSS, version 23.
Descriptive statistics, and frequencies were obtained in addition to completion of analysis
related to the research questions. Review of the literature yielded information related to
the assessment of pediatric BPD, susceptibility genes related to BPD, and the
neurobiological changes seen in BPD. The information from the literature review, and
data from the clinical survey were combined to guide the development of the clinical
tool.
Results
Sixteen respondents completed the required questions of the survey. Twenty
respondents began the survey; four either did not complete the required questions of the
survey or did not meet inclusion criteria. The sample was comprised of physicians (n=4,
25%), nurse practitioners (n=11, 68.8%), and a clinical nurse specialist (n=1, 6.2%). Half
of these clinicians treated patients across the lifespan (n=8, 50%), while some treated
child and adolescents only (n=6, 37.5%), and the remainder treated children, adolescents,
and young adults (n=2, 12.5%). The length of time these clinicians had been in practice
was also explored. The largest group of respondents had been in practice between six
and ten years (n=7, 43.8%). Other responses included: zero to five years (n=2, 12.5%),
eleven to twenty years (n=3, 18.7%), and twenty-one or more years (n=4, 25%).
Chi Square Analyses

Testing of the aforementioned research questions was completed by
performing Chi square analyses to determine if there were any significant
relationships between the assessment strategies used by clinicians and 1) the level
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of licensure of the clinician (mood journaling p=0.055, sleep journaling p=0.113,
rating scales p=0.379, lab studies p=0.195, will not diagnose p=0.660), 2) the
length of time the clinician had been in practice (mood journaling p=0.454, sleep
journaling p=0.917, rating scales p=0.450, lab studies p=0.468, will not diagnose
p=0.558), and 3) the age range the clinician treated (mood journaling p=0.558,
sleep journaling p=0.141, rating scales p=0.915, lab studies p=0.641, will not
diagnose p=0.180). None of the Chi square analyses resulted in significant
findings. None of the clinician respondents reported using imaging studies or
genetic testing regularly, so there are no p values for these measures. The
weakness of the sample size may have contributed to the lack of significance in
findings. This should be considered, and more data obtained in the future.

CHAPTER 5: DISCUSSION

Discussion Regarding Assessment Strategies
Overall, clinicians demonstrated consistency in their responses regarding the
symptoms assessed when diagnosing pediatric BPD. Though no statistically significant
findings were found between the assessment strategies used and the clinician survey data,
there was variation seen in the responses to the assessment strategies employed in
practice (see Appendix C, Chart 1). The variation in responses is either random or
related to a variable that was not studied. It is presumed that use of the clinical tool will
help to create greater consistency in the assessment strategies used. The final question of
the survey asked respondents whether or not a valid and reliable assessment tool would
be helpful to them, the majority of respondents (n=14, 87.5%) indicated that this would
be helpful to them. Based on this data obtained from the clinician study, there should be
openness to the diffusion of the tool and adoption of its process.
Data obtained regarding the family of origin showed some variation in responses
as well (see Appendix C, Chart 2), though not as dramatically as the assessment
strategies. A thorough family history should be consistently obtained due to the
heritability of BPD (Lichtenstein et al., 2009). The significance of these particular
aspects of family history are important in the assessment of pediatric BPD, further
consistency in this area of assessment could yield more effective diagnostics. Sleep
disturbance is a common symptom of BPD. Exploring patterns of this occurring in the
family of origin can be helpful in identifying BPD in the patient; this response showed
the greatest variation in responses in this section of questions.
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Clinicians were given the opportunity to provide free text responses regarding
how they distinguish between the aforementioned conditions that have similar symptoms
to pediatric BPD. The common themes contained in the responses received for this
question (n=10) included assessing for sleep disturbances, manic or grandiose periods,
and thorough assessment. One clinician responded that they would refer out any child or
adolescent that they suspected had BPD. Another free text question asked clinicians to
explain their perspective if they would not diagnose BPD in a child or adolescent. Two
clinicians created responses for this question, and both indicated that the clinician would
diagnose BPD in an adolescent if they met diagnostic criteria, but would not diagnose
BPD in a child. This question also did not require a response of the respondents.
Project Outcomes
A clinical tool has been created (see Appendix D) to aid in the assessment and
diagnosis of pediatric BPD. This tool has been created by synthesizing the data obtained
through the clinician survey, the information obtained during the literature review, and
the clinical knowledge of the author. The clinical tool is designed to be used in the
mental health setting, and could also be used in the primary care setting as a means of
determining when to refer for specialty assessment.
The clinical tool provides a comprehensive checklist of symptoms and prompts
the clinician to have the patient to mood journal. After this, the tool guides the clinician
to have the patient or their family to complete rating scales. Though any reliable and
validated screening tool is acceptable, information regarding the FIRM (Algorta et al.,
2013), and the Child Mania Rating Scale – Parent Version (CMRS-P) (Pavuluri, Henry,
Devineni, Carbray, & Birmaher, 2006) are included. Permission exists for the FIRM in
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academic and research contexts. The CMRS-P is available for download on the internet,
and permission for use was separately obtained by the author (Appendix E). If pediatric
BPD is still suspected, further evaluation is recommended. Laboratory studies are
recommended to rule out any underlying medical comorbidities that may contribute to the
clinical presentation; these would also allow for baseline levels to be obtained should
pharmacologic management commence in the future. Though the laboratory tests
ordered should be based upon the assessment of the clinician, some routine
recommendations to consider are: complete blood count with differential, comprehensive
metabolic panel, lipid panel, glycosylated hemoglobin, and thyroid stimulating hormone.
Other tests that may be warranted based on the individual patient presentation might
include: urine drug screen, urine human chorionic gonadotropin, prolactin, and vitamin
D. Testing for methylenetetrahydrofolate reductase (MTHFR) polymorphisms should be
considered on a case by case basis, as MTHFR polymorphisms are associated with mood
struggles, although this is not diagnostic of BPD (Gilbody, Lewis, & Lightfoot, 2007). It
is possible that with this level of thorough assessment, BPD could be ruled in or out.
However, if the clinical picture remains uncertain, MRI studies should be considered to
assess for neurobiological changes. Current research suggests that changes can be found
in the scans of BPD patients; particular consistency has been noted in changes in GMV
(James et al., 2011).
Validation of this screening tool will be completed in the future. After validity
and reliability have been established, broader dissemination, publication, and training
regarding the use of the tool will occur. It is hoped that the use of this tool will provide a
standardized platform for the assessment and diagnosis of BPD, and help to create greater
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diagnostic accuracy. It is anticipated that the tool will be available initially in pen and
paper format, and eventually developed into a smartphone application. Use of this tool
will provide an innovative approach to assessment, that will enhance the efficiency and
effectiveness of assessment. These attributes of the tool will be addressed during training
to aid in diffusion and adoption of the tool concepts.
Limitations
Crede (2010) reported the effects of random responding to the validity of
psychological tests and in research. The author noted that random responding could lead
to erroneous correlational relationships being identified. The converse could also be true,
that relationships that would have appeared stronger had the responses not been random
will not be identified. It is unknown if the effects of random sampling contributed to the
results of this project, further research is needed.
A low response rate from clinicians was another limitation of this project.
Cunningham, et al. (2015) noted that physicians are typically low responders to survey
research. The authors conducted survey research of various types of physicians to look at
response rates. Psychiatrists had by far the lowest return rate, and this was with a
supported, advertised, and structured dissemination of the survey (Cunningham et al.,
2015).
A perceived bias of this project could be that the clinician survey was
disseminated to many professional contacts of the author. However, these contacts
allowed the survey to reach several large university medical centers, several university
systems, the Ministry of Health in Singapore, several psychiatric hospitals, and a large
medical group. Additionally, a past president of the Northern California Regional

31
Organization of Child and Adolescent Psychiatry was able to disseminate the survey to
clinician members. Unfortunately, despite these seeming far-reaching contacts, very few
surveys were completed.
Recommendations for Further Study
Mental health providers like psychologists, therapists, and social workers can
diagnose pediatric BPD. These clinicians cannot order imaging studies or laboratory
studies, however, and as such, they were not included in this initial clinician survey.
They should be included in any future clinician surveys to understand their assessment
strategies, and to help garner more robust data. Due to the low number of clinician
respondents, continued study of clinician practices would be useful to see if any statistical
significance could be obtained and to re-enforce the findings that were discovered.
The most recent edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) brought updates to many pediatric mental health conditions. The
DSM-5 provides support for the diagnosis of pediatric BPD when the appropriate
symptomatology exists (American Psychiatric Association, 2013). One diagnostic
addition to the DSM-5 was that of disruptive mood dysregulation disorder (DMDD)
(American Psychiatric Association, 2013). This diagnosis captures many of the children
and adolescents that might have previously been mislabeled as having BPD. This is
considered a depressive disorder, however, not a cycling mood disorder like BPD.
Irritability in children and adolescents is a hallmark feature of both conditions. However,
a distinguishing factor is that the irritability in DMDD is persistently irritable, and in
BPD there will be periods of irritability followed by other distinguishable mood states
(American Psychiatric Association, 2013). Stringaris et al. (2010) noted that youth with
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severe mood dysregulation, as is seen in DMDD are very unlikely to develop a mixed or
manic episode. This type of episode would be seen relatively commonly in the BPD
population. Additionally, neurobiological differences can be appreciated in the brains of
patients with severe mood dysregulation, like DMDD, as compared to those with BPD,
when given the same tasks to complete (Adleman et al., 2011).
Ensuring that the clinical tool is sensitive to BPD is important. This will help
reduce misdiagnosis of other similarly presenting conditions like DMDD, ODD, CD, and
ADHD. This consideration is one reason that the FIRM was selected as one of the
recommended screening methods within the clinical tool. Research has shown that the
FIRM was more sensitive to BPD than other available scales, and was not sensitive to
ADHD (Algorta et al., 2013). The clinical tool now needs to be validated before
disseminating it into clinical practice. This is a crucial next research step to allow this
project to proceed.
Healthcare Improvement
Creating consistency in the evaluation of pediatric BPD will help to ensure that
the disorder is more accurately diagnosed. A more robust evaluation process will likely
help parents of potential BPD patients to be more accepting of the diagnosis, and thereby
help ensure early treatment. Early identification and treatment will help lead to more
positive outcomes for this vulnerable population (Maniscalco & Hamrin, 2008). The
intent is for this clinical tool to reach beyond psychiatry, and into primary care as well.
The assessment strategies will be clearly defined enough that those working in primary
care would be comfortable completing the assessment, and referring for treatment if a
diagnosis of BPD is likely.
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Conclusion

The development of the clinical tool provides a model for assessment that
can be used to diagnose BPD in the pediatric population. Data shows that the
incidence of the pediatric BPD has been rising (Littrell & Lyons, 2010). Current
literature has demonstrated that there is evidence for biological and genetic
changes that can be seen in the BPD patient, and the incorporation of the
expanding field of science into diagnostic practices is warranted. Clinician survey
data demonstrated that while clinicians seem to be consistent in their assessment
of symptoms of BPD, there is inconsistency in the use of other screening
strategies. Ultimately, the majority of clinician respondents indicated that a valid
and reliable clinical tool would be helpful to them professionally. This project
seeks to provide such a tool, and it is hoped that broad diffusion and adoption of
this tool will help to improve the care and outcomes of child and adolescent
patients everywhere.
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Term

Abbreviation

Analysis of Variance

ANOVA

Attetion Deficit Hyperactivity Disorder

ADHD

Bipolar Disorder

BPD

Brain-derived Neurotrophic Factor

BDNF

Calcium/Calmodulin Dependent Protein Kinase Kinase 2

CAMKK2

Catechol-O-Methyltransferase

COMT

Child Behavior Checklist

CBCL

Child Mania Rating Scale – Parent Version

CMRS-P

Children’s Global Assessment Scale

CGAS

Conduct Disorder

CD

Diagnostic Interview for Children and Adolescents – Parent

DICA-P

Version
Diagnostic and Statistical Manual of Mental Disorders, 5th

DSM-5

Edition
Disruptive Mood Dysregulation Disorder

DMDD

Dopamine Transporter

DAT

Family Index of Risk for Mood Disorders

FIRM
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Gray Matter Volume

GMV

Hamilton Rating Scale for Depression

HAM-D

Kiddie Schedule for Affective Disorders and Schizophrenia

K-SADS

Kiddie Schedule for Affective Disorders and Schizophrenia

K-SADS-E

- Epidemiologic
Kiddie Schedule for Affective Disorders and Schizophrenia
– Mania Rating Scale

KMRS

Kiddie Schedule for Affective Disorders and Schizophrenia
– Present and Lifetime

K-SADS-PL

Magnetic Resonance Imaging

MRI

Methylenetetrahydrofolate Reductase

MTHFR

Mini International Neuropsychiatric Interview

MINI

Mood Disorder Questionnaire - Parent

PMD-Q

Oppositional Defiant Disorder

ODD

Purinergic Receptor P2X 4

P2RX4

Purinergic Receptor P2X 7

P2RX7

Single Nucleotide Polymorphism

SNP

Structured Clinical Interview for DSM-IV

SCID

Toll-like Receptor 2

TLR2
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Transient Receptor Potential Cation Channel Subfamily M

TRPM2

Member 2
Unipolar Depression

UD

Young Mania Rating Scale

YMRS
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Appendix B – Clinician Survey
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Appendix C – Clinician Data Charts
Chart 1 – Assessment Strategies Employed

Assessment Strategies Employed
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Chart 2 – Family Screening

Family Screening
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Psychiatric Dx in Family Substance Abuse in Family
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Insomnia in Family
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Completed or Attempted
Suicide in Family
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Appendix D – Clinical Tool
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